UPDATE: Genmark Cuts Annual Revenue Guidance, Shares Slide
Genmark Diagnostics (NASDAQ: GNMK), the molecular diagnostics company, announced Monday that it was lowering full year revenue guidance to $30 million from $35 million.
Genmark noted that previously noted risks from its largest customer are playing out to the downside and thus Genmark expects lower revenue from this large customer, and thus overall revenue.
Genmark shares declined 6.56 percent after-hours to $10.25 per share after falling over eight percent intraday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.